Skip to content
DataLookout
Menu

PHOENYCS FLYNCT06617325

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 51 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 242 → 245 locations
  2. Minor Site details revised at 4 of 242 sites
  3. Notable Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 11 of 14 entries
    • Study sites revised (242)
  4. Minor Trial sites expanded: 238 → 242 locationsv48
  5. Minor Study sites: 236 to 238v47
  6. Minor Trial sites expanded: 233 → 236 locationsv46
  7. Minor Study sites: 231 to 233v45
  8. Minor Study sites: 230 to 231v44
  9. Minor Site details revised at 3 of 230 sitesv43
  10. Minor Study sites: 229 to 230v42
  11. Minor Study sites: 227 to 229v41
  12. Minor Study sites: 225 to 227v40
  13. Minor Trial sites expanded: 219 → 225 locationsv39
  14. Minor Trial sites expanded: 214 → 219 locationsv38
  15. Minor Study sites: 204 to 214v37
  16. Minor Study sites: 202 to 204v36
  17. Minor Study sites: 198 to 202v35
  18. Minor Secondary endpoints revised (14)v34
  19. Notable Eligibility criteria expanded, about 6 wordsv33
  20. Notable Eligibility criteria shortened, about 32 words
    • Secondary endpoints: 15 to 14
    v32
  21. Minor Study sites: 196 to 198v31
  22. Minor Study sites: 185 to 196v30
  23. Minor Study sites: 181 to 185v29
  24. Minor Study sites: 177 to 181v28
  25. Minor Study sites: 174 to 177v27
  26. Minor Study sites: 167 to 174v26
  27. Minor Study sites: 163 to 167v25
  28. Minor Study sites: 164 to 163v24
  29. Notable Primary and study completion dates: Sep 15, 2027 to May 31, 2028
    • Study sites: 159 to 164
    v23
  30. Minor Study sites: 155 to 159v22
  31. Minor Study sites: 149 to 155v21
  32. Minor Study sites: 142 to 149v20
  33. Minor Study sites: 140 to 142v19
  34. Minor Study sites: 133 to 140v18
  35. Minor Study sites: 132 to 133v17
  36. Minor Study sites: 129 to 132v16
  37. Minor Study sites: 128 to 129v15
  38. Minor Study sites: 122 to 128v14
  39. Minor Study sites: 119 to 122v13
  40. Minor Study sites: 114 to 119v12
  41. Notable Primary and study completion dates: Mar 2, 2027 to Sep 15, 2027v11
  42. Minor Study sites: 107 to 114v10
  43. Minor Study sites: 100 to 107v9
  44. Minor Study sites: 95 to 100v7
  45. Minor Study sites: 89 to 95v6
  46. Minor Study sites: 78 to 89v5
  47. Minor Study sites: 62 to 78v4
  48. Minor Study sites: 1 to 62v3
  49. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 16, 2024 to Nov 21, 2024
    v2
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 48
Timeframe: Week 48

Secondary (14)

Achievement of SRI 4 response at Week 48
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48
Achievement of LLDAS at Week 40 and maintaining LLDAS at Weeks 44 and 48
Change from Baseline to Week 48 in the FATIGUE-PRO Total score
Percentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at Baseline to ≤7.5mg/day at Week 36 and maintained through Week 48
Show 9 moreShow less
Achievement of BILAG 2004 improvement without worsening at Week 48
Change from Baseline in PGA at Week 48
Achievement of prevention of moderate/severe BILAG flares (moderate/severe BILAG flare-free) through Week 48
Change from Baseline in SLEDAI-2K at Week 48
Change from Baseline in FACIT-Fatigue score at Week 48
Percentage of participants with treatment-emergent adverse events (TEAEs) during the study
Percentage of participants with serious treatment-emergent adverse events during the study
Percentage of participants with treatment-emergent adverse events of special interest during the study
Percentage of participants with treatment-emergent adverse events of special monitoring during the study

Arms and interventions

Dapirolizumab pegolExperimental

Study participants will receive dapriolizumab pegol throughout the Treatment Period.

PlaceboPlacebo comparator

Study participants will receive placebo throughout the Treatment Period.

Drugs: DZP

Other: Placebo

Sites

245 sites in 23 countries

United States 63, China 36, Japan 31, Spain 15, Germany 14, Italy 13, Poland 11, Taiwan 8, Argentina 7, United Kingdom 7, South Korea 6, Denmark 4, Greece 4, Serbia 4, Canada 3, France 3, Mexico 3, Netherlands 3, Peru 3, Puerto Rico 3, Belgium 2, Chile 1, United Arab Emirates 1